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incontinence and mucus loss in the rectum mapping. For the 
IG-IMRT patients only mucus loss was significant in the anus 
mapping, while both mucus loss and proctitis were significant 
in the rectum mapping. Results for proctitis are illustrated 
for 3D-CRT (44% incidence) in the anus mapping (Fig. 1e, 
p=0.01) and for IG-IMRT (27% incidence) in the rectum 
mapping (Fig. 1f, p<0.01). Note that the largest dose 
differences are not necessarily most significant. In a region 
with large dose variations, random permutations can lead to 
large differences by chance. Figs. 1c and 1e indicate an 
effect of the extent of the intermediate dose region around 
the circumference of the anus. Figs. 1b and 1f show the 
effect of a longer intermediate dose region along the central 
axis. 
Conclusions: Significant differences in the local dose to 
rectal and anal surfaces were found between patients with or 
without various GI toxicities. The locations of such 
differences provide clues about variables which are relevant 
to the clinical outcome, and which may serve as a basis for 
subsequent dose-effect modeling. 
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Purpose/Objective: Acute dysphagia is a common toxicity, 
associated with (chemo)radiotherapy for head and neck 
cancer, with substantial quality of life implications. 'Late' 
dysphagia is thought to result predominantly as a 
consequence of acute toxicity and associated interventions. 
There are currently limited dose-response data on radiation-
induced acute dysphagia in the literature. The aim of this 
study was to train and validate NTCP models, providing 
reliable tools to accurately predict the severity of acute 
dysphagia for individual patients. 
Materials and Methods: Predictive models of moderate or 
worse (Common Terminology Criteria for Adverse Events 
grade 2 or 3) and severe (grade 3) acute dysphagia were 
trained using data from six clinical trials featuring a range of 
primary disease sites and treatment techniques. Toxicity 
outcome was defined as the peak grade of toxicity, which 
was scored weekly throughout radiotherapy and up to 4 
weeks post-treatment and additionally at 8 weeks post-
treatment. 266 patients were included in the analysis after 
excluding patients with two or more consecutive missing 
toxicity measurements. Pharyngeal mucosa dose-volume 
parameters, concomitant treatment and clinical factors were 
considered as model covariates. Logistic regression was used 
for classification. Lasso- and ridge-regularisation, class-
weighting and cross-validated grid search were employed. 
The models were validated internally (with nested 5-fold 
stratified shuffle split cross-validation) and externally (on 
independent data) to measure their performance, using area 
under the receiver operating characteristic curve as the 
performance metric. 
Results: Figure 1 summarises the dose-volume data. 
 
Model diagnostics using learning curves showed that the 
severe dysphagia model was under-fitting the data. It was 
thought that this might be due to insufficient 
characterisation of concurrent chemotherapy. The model was 
retrained using 115 patients who did not receive concurrent 
chemotherapy. Table 1 shows the internal and external 
validation scores. 
NTCP model Internal validation 
(Mean ± standard 
deviation) 
External 
validation 
Moderate or worse 
dysphagia 
0.89 ± 0.07 0.82 
Severe dysphagia 0.63 ± 0.07 0.71 
Severe dysphagia 
(Radiotherapy only 
patients) 
0.67 ± 0.09 0.70 
Table 1: Model performances. 
The models contained a range of dosimetric and other 
variables, with V45 and concurrent chemotherapy having the 
highest regression coefficients for the moderate or worse and 
severe dysphagia models, respectively. 
Conclusions: A high performance NTCP model, capable of 
accurately predicting moderate or worse acute dysphagia for 
individual patients, has been trained and validated. It can 
also be used for informed comparisons of dose distributions 
and treatment strategies. The performance of the severe 
dysphagia model did not improve when trained on 
radiotherapy only patients, suggesting that additional 
